ReviewMolecular oncology2019
Primary prevention: a need for concerted action.
Review in Molecular oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Applying the 5P framework to improve cancer prevention in European health systems.Journal of public health policy · 2026Article
- Making the BEST Decision-the BESTa Project: Description of the Design and Alpha Phases as Part of the Development of a Digital Decision Aid for Cancer Screening in Sweden.Journal of cancer education : the official journal of the American Association for Cancer Education · 2026Article
- Colorectal cancer risk: stereotypical assumptions and competing values - a qualitative study with the general public.BMC public health · 2026Article
- Developing evidence-based, cost-effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities.Molecular oncology · 2026Article
- Developing evidence-based cancer prevention recommendations: Methodology of the World Code Against Cancer Framework to create region-specific codes.International journal of cancer · 2026Review
- Healthy life style practice and its associated factors among public servants in Fiche town, Ethiopia.BMC public health · 2025Article
- Characterizing stakeholders in cancer primary prevention in European countries: an exploration of challenges and opportunities using a penta-helix framework.Frontiers in public health · 2025Article
- Article
- Review on novel toxicological effects and personalized health hazard in workers exposed to low doses of benzene.Archives of toxicology · 2024Review
- Mapping the European cancer prevention research landscape: A case for more prevention research funding.European journal of cancer (Oxford, England : 1990) · 2023Article
- The "Breast-4Y" web app for breast cancer prevention at young age: Development, evaluation, and validation.Internet interventions · 2023Article
- Engaging European society at the forefront of cancer research and care: How discussions at the 5Molecular oncology · 2023Article
- Cancer outcome research - a European challenge Part II: Opportunities and priorities.Molecular oncology · 2022Review
- Identifying Novel Causes of Cancers to Enhance Cancer Prevention: New Strategies Are Needed.Journal of the National Cancer Institute · 2022Article
- Development and validation of the MARA scale in Spanish to assess knowledge and perceived risks and barriers relating to breast cancer prevention.Cancer causes & control : CCC · 2021Article
- Revisiting Candidacy: What Might It Offer Cancer Prevention?International journal of environmental research and public health · 2021Article
- Sustainability and monitoring of the European Code Against Cancer: Recommendations.Cancer epidemiology · 2021Article
- The eleventh hour to enforce rigorous primary cancer prevention.Molecular oncology · 2021Article
- Towards a cancer mission in Horizon Europe: recommendations.Molecular oncology · 2020Article
- What will radiation oncology look like in 2050? A look at a changing professional landscape in Europe and beyond.Molecular oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The burden of cancer is increasing worldwide, and Europe is no exception in this regard. Cancer incidence rate for men in 2018, excluding nonmelanoma skin cancers, averaged over the 40 UN-defined European countries has been estimated as 436/100 000. For women, the estimated incidence rate is 332.6/100 000. Although mortality rates are declining in most European countries, the total number of cancer deaths continues to rise due to an increase in the number of older people in the age range when the cancer typically occurs. The increase in incident cases and cancer deaths increases the pressure on healthcare infrastructure and related costs, thus presenting a challenge to health service sustainability in countries. In the general population, there remains a perception of an ever-increasing cancer risk. Hence, treatment alone is not a solution to address the cancer burden. At the same time, recent estimates of preventable fractions of cancer suggest that about half of all cancer cases could be prevented through rigorous implementation of successful prevention measures, among other actions, by following the cancer prevention recommendations of the European Code against Cancer. Smoking alone explains almost half of all preventable cancers, and the scattered way of implementing tobacco control in Europe with still increasing numbers of lung cancers in women demonstrates the gap between prevention potential and effectively implemented prevention. Cancer prevention clearly needs more resources, stronger support from decision-makers and society, and a solid network to better speak with one voice. The newly established 'Cancer Prevention Europe' (Forman et al., ) offers promising opportunities for the latter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.